With the JP Morgan update season about to get in full swing, I thought it might be a good time to review the sequencing field and where we stand at the beginning of 2023. The big news was, of course, that after years of having a virtual monopoly, Illumina faces a bevy of new competitors....
Back when Illumina first announced they were going to acquire GRAIL, the general feeling in the M&A field was that this wouldn’t trigger any antitrust issues. I was asked if I could think of any difficulties. I didn’t claim back then that I was an antitrust expert (and still don’t), but I did wonder if...
2020 started pretty rough for PacBio with the Illumina acquisition being called off (albeit with a nice $98 cushion). Then the pandemic hit, forcing them to shut down for a while. Finally, mid-summer the CEO and CFO announced their retirements. My guess is they were all in on the merger and didn’t want to be...
Here’s my take on what we might see in 2020 for the sequencing platform market. This isn’t specifically about JPM, but I wanted to get this out ahead of the conference since it’s obviously one of the main venues for “big announcements”. Illumina 1) Merger/long reads I was all prepared to...
About five minutes after Illumina announced their intention to acquire PacBio, my phone started ringing with market analysts, fund managers, and journalists all looking for the answer to one question: Will this merger pass anti-trust review? While I can’t say whether it WILL, I can emphatically say that it SHOULD. Read on to see why...
Every so often someone will ask about the various “generations” of DNA sequencing or a company will claim to have the latest generation – 3rd, 4th, even “last”. (Hey, Genia, if you don’t come out with something soon, I’m going to start calling your platform “late” generation sequencing – as in “late to the party”...